Podcasts about PDAC

Sultan Ameerali shares insights on how he is approaching this mining sector, particularly focusing on gold and silver investments. He discusses personal investment strategies, the importance of understanding risk tolerance, and the challenges faced in jurisdictions like Mexico. Sultan emphasizes the need for investors to be aware of market dynamics and to make informed decisions based on their risk profiles. The discussion also touches on the upcoming PDAC conference.

Mining Stock Daily hosts Hugh Agra, CEO of Revival Gold, discussing the upcoming PDAC conference, market sentiment, and the company's projects, including Mercur and Beartrack-Arnett. They explore the current state of the mining industry, Revival Gold's work plans for 2026, and the potential for growth in their projects. The discussion highlights the importance of institutional involvement and the strategic direction of Revival Gold as they prepare for future developments.

CEO Tony Moreau of American Eagle Gold discusses the significant breakthrough drill results today from the NAK Copper-Gold-Molybdenum Porphyry Project in British Columbia, highlighting the unexpected high-grade mineralization found. The discussion covers the implications of these results for the project's future, including plans for extensive drilling to expand the mineralized area and the strategic focus on high-grade zones. Moreau also shares insights on upcoming news and market catalysts as the company prepares for the PDAC conference.

Recording date: 16th February 2026Gold mining companies are generating unprecedented levels of free cash flow, with major producers like Agnico Eagle reporting more than $11 million per day in Q4 2024 at an average realized gold price near $4,200 per ounce. With gold prices running approximately $800 per ounce higher in the current quarter, that figure is tracking toward $15 million or more per day - a level that is fundamentally reshaping how companies think about capital allocation.Speaking on the Compass podcast, Samuel Pelaez and Derek Macpherson of Olive Resource Capital argued that this cash flow environment gives producers the rare ability to pursue multiple priorities simultaneously: debt reduction, dividend increases, share buybacks, and acquisitions. That flexibility, they noted, sets the current cycle apart from previous periods in the sector.The discussion comes as the mining industry enters its most active conference season of the year. An institutional-focused gathering in Miami is followed shortly by PDAC in Toronto - the world's largest mining conference - beginning around March 1st. Both events are expected to accelerate M&A discussions, as corporate development teams from major miners hold direct meetings with junior company management. Pelaez and Macpherson suggested that transaction announcements could coincide with or immediately follow PDAC.In the near term, Chinese New Year - which began February 17th - introduces a period of thin liquidity across commodity markets as Chinese exchanges close for the week. The hosts characterized any resulting price volatility as mechanical rather than fundamental, and suggested investors treat sell-offs in stocks they already favor as potential entry points.On the macro side, four factors continue to underpin the commodity bull market: expanding US manufacturing PMIs, resilient employment data, continued global liquidity growth, and a US fiscal deficit of approximately $800 billion - the third largest on record - reinforcing the case for hard assets even as the economy grows.Sign up for Crux Investor: https://cruxinvestor.com

This week's episode features Alon Olsha, Senior Analyst for Metals & Mining at Bloomberg Intelligence, in conversation with host Adrian Pocobelli about the recent failed merger discussions between Rio Tinto and Glencore. Olsha explains how the sheer complexity of combining two global mining giants proved a major obstacle, alongside issues such as valuation gaps and management structure. He also traces the history of the two companies and their long-standing merger speculation, examines their respective portfolios, and analyzes how a combined entity might have complemented each business. All this and more with host Adrian Pocobelli. This week's Spotlight features Ricky Chan and Gary Baschuk, Co-Heads of Mining at PearTree Canada, discussing the state of mining finance, the role of flow-through shares, and what they're expecting at this year's PDAC conference. To learn more, visit: https://peartreecanada.com/ “Rattlesnake Railroad”, “Big Western Sky”, “Western Adventure” and “Battle on the Western Frontier” by Brett Van Donsel (⁠www.incompetech.com⁠). Licensed under Creative Commons: By Attribution 4.0 License ⁠creativecommons.org/licenses/by/4.0⁠ Apple Podcasts:⁠ https://podcasts.apple.com/ca/podcast/the-northern-miner-podcast/id1099281201⁠ Spotify:⁠ https://open.spotify.com/show/78lyjMTRlRwZxQwz2fwQ4K⁠ YouTube:⁠ https://www.youtube.com/@NorthernMiner⁠ Soundcloud:⁠ https://soundcloud.com/northern-miner

This week's episode features Karen Rees, President of the Prospectors & Developers Association of Canada (PDAC), in conversation with host Adrian Pocobelli about this year's PDAC conference in Toronto. Rees describes the strong sense of momentum across the mining industry and highlights the expanded conference floor, which will accommodate more exhibitors than ever. She also offers practical advice on how to navigate the event—“wear comfortable shoes”—and discusses key features including the Investor Exchange, the trade show, and the North and South buildings. To attend the conference, visit: https://pdac.ca/ All this and more with host Adrian Pocobelli. This week's Spotlight features Kerem Usenmez, President and CEO of Volta Metals, who discusses the company's Springer rare earths and gallium project in Ontario. To learn more, visit: https://www.voltametals.ca/ “Rattlesnake Railroad”, “Big Western Sky”, “Western Adventure” and “Battle on the Western Frontier” by Brett Van Donsel (⁠www.incompetech.com⁠). Licensed under Creative Commons: By Attribution 4.0 License ⁠creativecommons.org/licenses/by/4.0⁠ Apple Podcasts:⁠ https://podcasts.apple.com/ca/podcast/the-northern-miner-podcast/id1099281201⁠ Spotify:⁠ https://open.spotify.com/show/78lyjMTRlRwZxQwz2fwQ4K⁠ YouTube:⁠ https://www.youtube.com/@NorthernMiner⁠ Soundcloud: https://soundcloud.com/northern-miner

Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.In this episode, you'll learn:The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)Strategies for building more predictive, clinically relevant research models (06:09)Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)Strategic insight:Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.Connect with Bryan Miller:LinkedIn: www.linkedin.com/in/bryan-miller-148344aaCrown Bioscience: www.crownbio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Bradda Head Lithium Ltd (AIM:BHL, OTC:BHLIF, TSX-V:BHLI, FRA:8CD1) executive chairman Ian Stalker talked with Proactive's Stephen Gunnion about the company's strategic partnership with Rio Tinto's Kennecott division and what it means for the Whistlejacket lithium project in Arizona. Stalker explained that Bradda Head is earning up to 60% ownership in the Whistlejacket project, with Rio Tinto maintaining an interest and offering support. He emphasised the significance of having a major like Rio Tinto involved, noting that “RTZ are a huge supporter of what we're doing.” According to Stalker, the partnership follows nearly a year of discussions, starting from the PDAC conference in Toronto. He said Bradda was selected because of its track record, professional management, and previous success in the US lithium space, particularly in Arizona. The proximity of Whistlejacket to Bradda's existing San Domingo project creates potential synergies, enabling the company to leverage a single management structure and streamlined operations. Stalker also addressed the scale of the opportunity, stating that while the project may not be a tier-one asset, it fits well in the tier two or three category. He said the goal now is to grow a sizable and economic lithium resource by combining San Domingo and Whistlejacket. He further highlighted the company's diversified lithium portfolio in Arizona, noting, “Bradda itself is not only hard rock lithium in the Spodumene scenario, we still have our existing NI 43-101 compliant resource and the lithium in clays.” For more updates on Bradda Head Lithium Ltd and other resource sector interviews, head over to Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future content. #BraddaHeadLithium #RioTinto #LithiumMining #ArizonaLithium #WhistlejacketProject #SanDomingo #BatteryMetals #MiningStocks #LithiumInvestment #ResourceSector

In this episode, I welcome back Mike Burke, Director and Vice President of Corporate Development at Sitka Gold (TSX.V: SIG | OTCQB: SITKF | FRE:1RF), for a deep dive into the final results of the 2025 drill season and a look ahead at the company's major 2026 drill plans. Following the January 22nd news release, the team has now confirmed mineralization across the entire 1.1-kilometer strike length at the Rhosgobel discovery, part of their flagship RC Gold Project in the Yukon. Key Discussion Points: Rhosgobel Strike Consistency: Confirmation that mineralization is now proven over a 1.1km footprint and remains open in all directions and at depth. The Maiden Resource Estimate: The timeline for the initial MRE, expected to be released ahead of PDAC in Q1 2026. The Tungsten Advantage: How the inclusion of tungsten trioxide as a critical mineral byproduct could "smooth out" the grade and add significant byproduct value. 2026 Exploration Strategy: Details on the upcoming 60,000-meter drill program, including expansion at Rhosgobel and testing high-priority targets like Blackjack and Saddle.   If you have any follow up questions for Mike please email me at Fleck@kereport.com.    Click here visit the Sitka Gold website to learn more about the Company - https://sitkagoldcorp.com/   ------------------ For more market commentary & interview summaries, subscribe to our Substacks: The KE Report - https://kereport.substack.com/ Shad's Substack - https://excelsiorprosperity.substack.com/   Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or investment product. Investing in equities, commodities, really everything involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioeconomic drivers of disparate patient outcomes, and translational research focusing on factors like the tumor microenvironment.Trevino stressed the idea of pancreatic cancer care as a “team science,” rejecting a “silo mentality” that involves handing off a patient from one department to the next. Because surgical approaches by themselves have remained “limited” in pancreatic cancer for the past 20 to 30 years, he emphasized continued collaboration with medical oncologists, radiation oncologists, and translational scientists to enhance patient quality of life. Regarding disparities, Trevino noted the importance of recognizing various barriers to treatment access among those in rural communities as well as unequal outcomes across different racial and ethnic groups of patients, including worse survival among Black populations. Additionally, in the face of continuously rising PDAC incidence, he stressed additional training across the board on how to detect the red flags associated with disease.“…There has to be a ton of education for our patients and our physicians who see patients on a primary level to know what those red flags are when a patient comes to their clinic. Early detection of early lesions that could eventually turn into pancreatic adenocarcinoma is going to be the key to survival, ultimately. [If we] catch it before it becomes a cancer, we solve a huge problem,” Trevino stated. “Early detection of early lesions is key.”Trevino is chair of the Division of Surgical Oncology and an associate professor in the Department of Surgery at VCU School of Medicine as well as surgeon-in-chief and Walter Lawrence, Jr., Distinguished Professor of Oncology at VCU Massey Cancer Center.

Interview with Jeremy Gillis, Director Capital Markets of Sendero ResourcesOur previous interview: https://www.cruxinvestor.com/posts/sendero-resources-tsxvsend-drilling-high-grade-targets-in-argentinas-vicua-copper-district-5346Recording date: 10th December 2025Sendero Resources has emerged as a compelling exploration story following a comprehensive restructuring that brought together mining industry veterans to advance a district-scale land position in Argentina's proven Vicuña copper-gold belt. Trading at approximately $30 million market capitalization with just 24 million shares outstanding, the company controls 211 square kilometers along the same structural corridor as billion-dollar discoveries including Filo del Sol, Josemaría, and Los Helados.The transformation began in 2024 when new leadership overhauled the struggling junior explorer, recruiting CEO Alex Gostevskikh (ex-Kinross, Centerra) and Steven McMullan, a PDAC prize-winning geologist whose discovery work contributed to Kamoa—now the world's fourth-largest producing copper mine. This production-focused technical team brings a critical economic lens to evaluating mineralization from the earliest exploration stages.What distinguishes Sendero's approach is comprehensive data reprocessing. The team analyzed 40 years of historical exploration data from the property—including 16,000 meters of drilling that showed mineralization throughout with no blank holes—plus 300,000 meters of drilling data from neighboring Filo del Sol. This work identified specific pathfinder elements and structural controls consistent between major district discoveries and Sendero's ground, including anomalous silver signatures that mirror Filo del Sol's high-grade zones.The company has attracted blue-chip mining investors including Peter Marrone (Yamana Gold, Allied Gold) and Argentine billionaire Eduardo Elsztain, who participated in progressively higher-valuation financings. The most recent $4 million raise closed at $0.95 per share with no warrants—a significant premium to earlier rounds. With management and strategic investors controlling 60-70% of shares, minimal public float exists.Sendero plans a focused 3,600-meter drill program for Q1 2026, targeting a newly identified area along a fault corridor that management believes hosts discovery-scale mineralization. Rather than testing multiple historical targets, the six-hole program concentrates on what the team considers the highest-probability opportunity for a significant find in this world-class gold-copper district.View Sendero Resources' company profile: https://www.cruxinvestor.com/companies/sendero-resourcesSign up for Crux Investor: https://cruxinvestor.com

What You Need To Know:First prototype targeted for Q3–Q4 2026, with subsystems already operationalPlanned output of ~20 kg of hydrogen/day, enough to power 10 homes or 80–100 drone flights dailyStrong probability of grant funding to build the first full-scale systemPre-order demand expected as demonstrations roll outHPQ holds exclusive North American commercialization rightsHere's how HPQ is positioning METAGENE™ as a cost-effective, transport-free hydrogen solution for high-value remote and defense markets.HPQ Silicon and its affiliate Novacium are moving closer to a breakthrough in decentralized clean power: hydrogen generated on-site without electricity, storage tanks, or hazardous transport. The METAGENE™ system converts an aluminum–silicon block into hydrogen at the point of use, addressing the sector's largest economic constraint — hydrogen becomes uneconomical once transported more than 200 kilometers from the production source.By eliminating transport entirely, METAGENE™ can deliver hydrogen at significantly lower cost, with internal analysis suggesting potential savings of up to 50% in remote regions.HPQ's collaboration with AD-VENTA adds further acceleration. Instead of developing compressors and high-pressure modules internally, HPQ will integrate its reactors directly into AD-VENTA's existing hydrogen station platform, reducing engineering time and technical risk.METAGENE™ is built for environments where traditional hydrogen supply chains fail — either due to cost, safety, or regulatory restrictions. Defense applications, particularly long-endurance hydrogen-powered drones, represent HPQ's first and most active commercialization lane. Pressurized hydrogen cannot be flown into these locations, but METAGENE™ can be deployed safely, on-site, and on demand.Expected output of 20 kg/day translates to roughly 400 kilowatt hours of electricity when paired with high-efficiency fuel cells. This is enough to power remote medical stations, military installations, or high-volume drone operations used in pipeline and high-voltage grid inspections. These are markets where reliable, clean, long-duration energy is both scarce and expensive.HPQ's progress is reinforced by independent validation from AD-VENTA's CEO, Jean-Luc Mussot, who reviewed the system before entering the partnership:“It represents an important advancement for decentralized high-pressure hydrogen production, especially in off-grid environments where heavy infrastructure is impractical.”For investors, third-party technical endorsement strengthens confidence in the system's viability as HPQ approaches the commercialization phase.HPQ reports that the METAGENE™ reactor design is complete, and integration with AD-VENTA is underway. A commercial prototype is scheduled for Q3–Q4 2026, supported by expected grant funding. The company anticipates that pre-orders — particularly from drone, defense, and remote industrial operators — may begin once the demonstration unit is unveiled.An explainer video is planned for early 2026 to support outreach at major mining and technology events, including the PDAC conference, where HPQ intends to showcase concept demonstrations and early proof-of-performance footage.With a clear development timeline, demonstrated cost advantages, and multiple high-value markets demanding alternatives to traditional hydrogen transport, HPQ is positioning METAGENE™ as a practical solution to longstanding energy challenges. The ability to pair on-demand hydrogen generation with AD-VENTA's proven high-pressure infrastructure gives HPQ a credible and accelerated path toward commercialization — and a compelling case for investor attention as the technology moves toward market entry.A NEW APPROACH TO REMOTE ENERGY GENERATIONWHY THIS MATTERS FOR EMERGING COMMERCIAL MARKETSVALIDATION FROM A HYDROGEN INDUSTRY EXPERTMILESTONES AND THE PATH TO MARKETTHE OUTLOOK: A TECHNOLOGY APPROACHING INFLECTION

Send us a textTwo sentences from PDAC can potentially change the course of manufacturing history for O & P: additive manufacturing is now explicitly acceptable for coding prosthetic devices that meet existing HCPCS descriptions. We unpack what that clarity means for clinicians, patients, vendors, and payers, and how to adopt 3D printing.• Why PDAC's language ends the gray area for 3D‑printed prosthetics• What PDAC and DME MAC do and how they shape coding• How to match additive devices to existing L code descriptions• Documentation discipline to avoid denials and audits• FDA's proactive stance and signals to industry• Medicare vs Medicare Advantage realities for reimbursement• When new codes help vs when they stall at zero pay• Scaling care amid workforce shortages using digital workflows• Using additive to improve fit, speed, and repeatability• Practical steps to start: scanning, CAD, materials, recordsSpecial thanks to Advanced 3D for sponsoring this episode.Support the show

Join Julia Mayerle and Francisco X. Real (Paco) as they reflect on the first-ever Digestive Disease Mechanism (DDM) Summit, introduced during UEG Week 2025 in Berlin. In this special episode, they discuss how the DDM Summit brought together leading scientists and clinicians to explore the mechanisms driving GI cancers — from colorectal to pancreatic and liver cancer. Hear how cutting-edge discoveries in genomics, metabolism, and tumour microenvironment are already shaping translational research and clinical trials. Julia and Paco also share highlights from the meeting, including exciting poster sessions, emerging collaborations, and their vision for the next DDM Summit focusing on inflammation in GI disease. - 08:00 The evolution of colitis-associated colorectal cancer Trevor A. Graham (United Kingdom) - 09:45 Tumour cell plasticity and immune evasion in metastatic colorectal cancer. Eduard Batlle Gomez (Spain) - 11:45 Cutting the nerve supply to pancreatic cancer Andreas Trumpp (Germany) - 16:40 Neutrophil-driven inflammation in PDAC progression Dieter Saur (Germany) - 17:30 Exploring the therapy-associated tumour immune microenvironment across the spectrum of HCC Tom Bird (UK) - 17:45 Intermittent fasting in MASH and liver cancer Suchira Gallage (Germany) - 17:50 Metabolic drivers of cancer and obesity-related diseases Guadalupe Sabio (Spain)

Send us a textWe share a personal update and then dive into how injuries, curiosity, and tough feedback shaped a modular myoelectric hand that is lighter, repairable in minutes, and priced for wider access. Ryan Saavedra of Alt-Bionics walks through additive manufacturing choices, PDAC approval, and a roadmap linking prosthetics with humanoid robotics.• user and clinician pain points shaping design choices • modular finger architecture for fast field repairs • nylon 12 and MJF for strength, weight, and cost • tolerancing to reduce lash and improve reliability • pricing philosophy, PDAC approval, and reimbursement nuance • EMG control foundations, firmware over AI for stability • balancing service bureaus vs in-house manufacturing • funding from bootstrap to mission-aligned investors • product roadmap focused on hands and higher DoF • cross-pollination between prosthetics and roboticsSpecial thanks to Advanced 3D for sponsoring this episode.Support the show

Immunotherapy is not usually effective against pancreatic cancer (PC), but a new study published in Oncotarget (Volume 16, 2025) highlights rare cases where it did help. These examples, though uncommon, may offer valuable insights for future treatment. Pancreatic Cancer and Immunotherapy Pancreatic cancer is often diagnosed at an advanced stage, which limits treatment options and contributes to its poor prognosis. While chemotherapy remains the standard treatment, it usually offers only modest benefits in terms of survival. Immunotherapy—an approach that activates the immune system to fight cancer—has been effective in other cancers but has shown limited success in PC. This is largely due to the tumor's ability to suppress immune responses and create an environment that protects it from attack. Currently, these drugs are only approved for a small subset of patients whose tumors have a specific genetic feature called high microsatellite instability (MSI-high), found in just 1 to 2 percent of cases. The Study: Pancreatic Cancer Immunotherapy Responders The study, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence,” was led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center. The researchers examined medical records from 14 patients with pancreatic ductal adenocarcinoma (PDAC) who had responded unexpectedly well to immune checkpoint inhibitors—drugs that help reactivate immune cells to attack cancer. The drugs included PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting tumor-associated macrophages. To find these rare cases, the research team contacted 471 oncologists from 91 major U.S. cancer centers between 2020 and 2021. Full blog - https://www.oncotarget.org/2025/09/11/immunotherapy-response-in-pancreatic-cancer-what-a-new-study-reveals/ Paper DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Abstract video - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic adenocarcinoma, immunotherapy, exceptional responders, microsatellite instability, survival To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O'Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:How patients often present with disease-related symptomsTreatment selection considerations for the first-line and second-line settingHow to approach palliative care discussions with patientsEmerging therapies that are showing promise in this settingPresentersPaul E. Oberstein, MDAssociate Professor of MedicineSection Chief, GI OncologyPerlmutter Cancer CenterNYU Langone HealthNew York, New YorkMark O'Hara, MDAssociate Professor of MedicineDivision of Hematology and OncologyUniversity of PennsylvaniaPhiladelphia, PennsylvaniaZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program: https://bit.ly/45NdBTx

This week's episode features Rim Fayjhi, Director of Women in Mining Canada, and Jennifer Berger, Board Advisor for Women in Mining Sudbury. They share how to participate in this year's Trailblazer Awards, to be presented at PDAC, and discuss the state of women in the mining industry. Fayjhi reflects on her recent experience studying mining engineering at university, while Berger draws on two decades of industry experience. All this and more with host Adrian Pocobelli. This week's Spotlight features Craig West, CEO of Coldblock Technologies Inc., who discusses the company's innovative infrared-based assaying technology. Learn more at: https://coldblock.ca/  “Rattlesnake Railroad”, “Big Western Sky”, “Western Adventure” and “Battle on the Western Frontier” by Brett Van Donsel (⁠www.incompetech.com⁠). Licensed under Creative Commons: By Attribution 4.0 License ⁠creativecommons.org/licenses/by/4.0⁠ Apple Podcasts:⁠ https://podcasts.apple.com/ca/podcast/the-northern-miner-podcast/id1099281201⁠ Spotify:⁠ https://open.spotify.com/show/78lyjMTRlRwZxQwz2fwQ4K⁠ YouTube:⁠ https://www.youtube.com/@NorthernMiner⁠ Soundcloud:⁠ https://soundcloud.com/northern-miner

Alternative business models in mineral exploration and mining can build value for communities, benefit resource companies and influence perceptions in our industry. This episode highlights two innovative companies who are changing the business of mining:  Nations Royalty and VRIFY. Nations Royalty, a TSXV-listed royalty company, is focused on creating royalty diversification for indigenous people. Kody Penner, VP of Corporate Development at Nations Royalty, joined host Halley Keevil to explain the background and the business model.  First, he tells his own story as an indigenous person growing up surrounded by British Columbia's mining industry. The company,  Nations Royalty, is the first indigenous-owned mining royalty company, and their indigenous ownership and management make them unique. He elaborates on how they balance corporate goals with indigenous goals and values, how they are creating wealth for indigenous groups, and what is next for the company in the future. Next, Steve de Jong, CEO of VRIFY, talks about the company's history and how they came to their current business model as an AI-focused mineral exploration and software service provider. Launching at PDAC in 2024 with just 4 clients, VRIFY now has 30 clients and gains 5-7 new clients per month. Steve discusses how their team of geoscientists and machine learning experts utilize every scrap of data from a company in order to build predictive models that deliver targets to their clients. He reviews the many ways in which VRIFY is unique in the industry, including the symbiotic relationship they have with clients, enabling them to use their proprietary software alongside the VRIFY team. He hints at some exciting current and future successes that the listener should stay tuned for. Steve believes we are about to enter into a period where AI will be ubiquitous in the mining industry, and VRIFY will be ahead of the game.   Theme music is  Confluence by Eastwindseastwindsmusic.com Come join us in Brisbane, Australia for SEG 2025, September 26-29th. This will be a dynamic conference with cutting edge science, new discoveries, technology and more. Opportunities for networking and learning include several workshops and field trips before and after the event, relaxed social events and of course the conference itself. See you there!

In this JCO Article Insights episode, host Jospeh Mathew summaries Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial, by Palmer, et al published December 5, 2024. Transcript Joseph Matthew: Hello and welcome to the Journal of Clinical Oncology Article Insights. I'm your host, Joseph Matthew, and today we will be discussing the article "Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma with Adjuvant Gemcitabine plus Capecitabine Compared to Modified FOLFIRINOX from the ESPAC-4 and the PRODIGE 24 Trials" by Dr. Palmer et al. To summarize the relevant evidence, the ESPAC-4 was a European phase 3 multicenter randomized clinical trial published in 2017 comparing adjuvant gemcitabine and capecitabine (GemCap) with gemcitabine monotherapy following macroscopic margin-negative resections for operable pancreatic ductal adenocarcinoma (PDAC). The trial had included non-metastatic patients aged 18 years or older, World Health Organization (WHO) performance scores of 2 or less, creatinine clearance of at least 50 mL/min, and a life expectancy of over three months who had not received any prior anticancer treatment. Patients who had undergone R2 resections were selectively excluded. Eligible participants were randomized 1:1 within 12 weeks of pancreatectomy to one of the two treatment arms, with chemotherapy initiated within two weeks from the date of randomization. The regimens involved six cycles, each lasting four weeks, for an overall duration of 24 weeks. In the monotherapy arm, gemcitabine dosed at 1 g/m² was given as an intravenous infusion once a week for three weeks, followed by one week off. In the GemCap arm, capecitabine dosed at 1660 mg/m² was added to gemcitabine, given daily for three weeks, followed by one week off. Patients were followed up every three months, with the primary endpoint being overall survival (OS). The study showed that at a median follow-up of 43.2 months, GemCap was associated with a significantly longer OS than gemcitabine alone. Subsequently, in 2018, the Phase 3 randomized PRODIGE 24 trial was conducted in centers across France and Canada, comparing adjuvant modified FOLFIRINOX (mFOLFIRINOX) with gemcitabine in a similar subset of patients with resected PDAC and reported longer OS with the mFOLFIRINOX regimen. This study, however, had more restrictive eligibility criteria when compared to ESPAC-4, including patients aged under 80 years, WHO performance status of 0 or 1, with no significant cardiovascular disease, and a postoperative serum CA 19-9 of less than 180 U/mL. There was hence a subset of ESPAC-4 patients who did not meet the eligibility criteria for mFOLFIRINOX as set by the PRODIGE 24. The present study was conducted to estimate the overall 5-year survival rates for patients of ESPAC-4 receiving GemCap and gemcitabine, further stratifying survival in either arm according to the status of the surgical margins (R status) and the resected nodes (N status), and also to investigate whether GemCap retained a survival benefit over gemcitabine in PRODIGE 24-ineligible patients. A total of 732 patients, evenly distributed between both arms, were followed up for a median period of 104 months. Adjuvant GemCap was found to retain its survival advantage over gemcitabine, with a significantly longer median OS of 31.6 months when compared to 28.4 months with gemcitabine alone. Further subgroup analysis was performed with reference to the resection margins and the nodal status. As a reminder, in the ESPAC-4 trial, 60% of patients were found to have microscopically positive margins (an R1 resection), and 80% were node-positive. The difference in survival was greater in patients undergoing microscopic margin-negative resections (R0) who experienced a median OS of 49.9 months with GemCap when compared to 32.2 months with gemcitabine. Node-negative patients also had a significantly greater 5-year OS rate with GemCap of 59% versus 53% with gemcitabine monotherapy. However, it is important to note that no significant difference in survival outcomes was observed in margin-positive (R1) or node-positive patients in the two arms. The investigators also evaluated GemCap in the subgroup of 193 patients (comprising 26.4% of the ESPAC-4 cohort) who were not considered to have met the eligibility criteria for PRODIGE 24. The survival benefit of combination therapy was retained in this group, with patients receiving GemCap experiencing a median survival of 25.9 months compared to 20.7 months with adjuvant gemcitabine. Although cross-trial comparisons have limited validity, good agreement was noted in adverse grade 3 or greater toxicity associated with the control gemcitabine arms of ESPAC-4 and PRODIGE 24, serving as the basis for a qualitative comparison of toxicities between mFOLFIRINOX and GemCap. Neutropenia was more prevalent in the GemCap arm, affecting 40.8% of patients compared to 28.4% with mFOLFIRINOX. However, granulocyte colony-stimulating factor (G-CSF) was administered to 62.2% of patients in PRODIGE 24. Palmar-plantar erythrodysesthesia (PPE) was also more prevalent with GemCap. Patients on mFOLFIRINOX were more likely to observe grade 3 or greater fatigue, diarrhea, nausea and vomiting, sensory peripheral neuropathy, and paresthesias. The investigators concluded that GemCap was the standard adjuvant treatment for patients with PDAC undergoing an upfront resection who were not feasible for mFOLFIRINOX. Further exploratory analysis revealed that patients under the age of 70 who had undergone a microscopic margin-negative (R0) resection for node-negative PDAC were likely to derive an OS benefit from the addition of capecitabine to gemcitabine in the adjuvant setting. In contrast, mFOLFIRINOX would be more effective than gemcitabine in patients with positive margins (R1) or involved nodes, as per the PRODIGE 24 trial. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Glenn Jessome, President and CEO of Silver Tiger Metals (TSX.V:SLVR – OTCQX:SLVTF), joins us to unpack the key takeaways from the Swiss Mining Institute (SMI) conference, the sentiment from retail and institutional investors in Europe, the continued permitting improvements from the new political administration in Mexico, and the ongoing exploration and development work at its 100% owned, silver-gold El Tigre Project.   There appears to a be robust European appetite to invest in the precious metals and gold and silver stocks, and Glenn notes that the commodities funds as well as generalist funds are finally seeing capital inflows to invest into PM stocks.  Investors are also opening up to Mexico as a mining jurisdiction, now that more permitting progress is announced, and we recap some of the constructive comments from Fernando Aboitiz, Head of the Extractive Activities Coordination Unit, Ministry of Economy, during the Mexico Mining Forum 2025 PDAC.   Wrapping up we focus on the work the Company is continuing to do as they await their open-pit permits, where Glenn is lining up and analyzing financial term sheets for the capex needed to build the open-pit mine at El Tigre, and the company is continuing to drill from underground targeting the high-grade silver veins, and the Sulfide and Shale Zones that will feed into the upcoming PEA on the second phase of underground mining.   If you have any follow up questions for Glenn about Silver Tiger, then please email me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Silver Tiger Metals at the time of this recording, and may choose to buy or sell shares at any time.   Click here to follow the latest news from Silver Tiger Metals

Michael Steinmann, CEO of Pan American Silver, attributes record-high gold prices to global de-dollarization and central bank buying. “The fear of all these countries de-dollarizing and all the central banks that are buying gold... that's really the reason why we see that all-time high gold price happen,” he tells Daniela Cambone at the PDAC conference in Toronto in early March.Questions on Protecting Your Wealth with Gold & Silver? Schedule a Strategy Call Here ➡️ https://calendly.com/itmtrading/podcastor Call 866-349-3310

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to recap his key takeaways from the Prospectors and Developers Association of Canada (PDAC) conference in Toronto earlier this month.   He shares how he approaches getting the most out of conferences, and what kinds of questions he can ask management teams when he is in his one on one meetings. Additionally, Erik shares with us his observations on how hot trending stocks with recent newsflow got repeatedly discussed in conversations, have the more crowded booths, and saw shareprice action around the conference. Conversely, he points out how other companies with legacy projects and less regular newsflow remain not so hot, where sometimes their prior quality work has been forgotten about, and they had less of a buzz. This ties into a broader discussion on investor sentiment and herd behavior within the resource sector, the power of the network effect, and the separation of quality companies from more speculative ones as this bull market continues to pick up speed.   Click here to visit Erik's site – The Hedgeless Horseman

Send us a textDmitry Silversteyn provides his impressions of the 2025 PDAC conference in Toronto and highlights some of the hot topics attendees were discussing at this three-day event. 

In this episode from PDAC 2025, Howard provides corporate updates and market insights from players in the lithium, copper and deep-sea mining industries. CEO Gabriel Rubacha discusses Noa Lithium Brines' progress and funding status for 2025 plans, including a $13.5 million raise and confidence in fully funding their projects. Craig Shesky, CFO of the Metals Company, details their milestones in deep-sea nodules for nickel, manganese, and cobalt, underpinned by supportive US administration policies and strategic partnerships. Mitch Thomas, CEO of of Solis Minerals, outlines their transition back to copper exploration in Peru and their recent $4.5 million fundraising. CHAPTERS

In this episode at PDAC 2025, we interact with Power Metals' Chairman Johnathan More, CEO Haydn Daxter and Winsome Resources' Managing Director, Chris Evans. The discussion covers Power Metals' recent high-grade cesium discoveries, significant market growth from a 40 million to 200 million market cap, and its impact on the cesium market dominated by China. Johnathan and Haydn also address the strategic initiatives, potential for billion-dollar valuation, and plans for North American cesium industry growth. Additionally, the episode delves into cesium applications, unique mineral properties, and partnerships, including with Canaccord Genuity, aimed at advancing the company's goals. The conversation highlights the collaborative efforts with the Ontario government, indigenous partners, the future path to production as well as Winsome's investment thesis in Power Metals. CHAPTERS

  Welcome to The KE Report Weekend Show!   On this weekend's show we focus on the continued decline in US markets and recap the...

Welcome to The KE Report Weekend Show!   On this weekend's show we focus on the continued decline in US markets and recap the recent PDAC conference looking for opportunities in metals stocks.    If you enjoy the weekend show please go back through our website (https://www.kereport.com/), Podcast (https://rebrand.ly/KER-Podcast) and YouTube Page (https://www.youtube.com/@theKEReport) to listen to all our market commentary and company interviews. Please subscribe and leave us a review.   Segment 1 & 2 - Rick Bensignor, President of Bensignor Investment Strategies kicks off the show by providing a detailed analysis of the current market trends. Rick predicts potential lower targets for the S&P 500 and explains how positioning and market psychology play significant roles. He also discusses the recent performance of the US dollar, international markets, gold, and gold equities. Additionally, the conversation touches on the influence of political events and comments on the future of cryptocurrencies. Click here to visit the In The Know Trader website.   Segment 3 & 4 - Brian Leni, Editor of the Junior Stock Review, wraps up the show with a recap of the metals conferences MIF and PDAC) in Toronto over the last week and a half. We discuss what metals were the focus at the conferences (all about gold) and the types of metals stocks he is focusing on. These include select prospect generators and development plays. Click here to visit the Junior Stock Review website to keep up to date on what Brian is investing in.  

Bill Powers and Brian Leni share junior mining insights about PDAC, Metals Investor Forum, the multi-bagger process, and much more in this MSE episode. Bill discusses how Brian 20-bagged on Bill's loss. And Brian reveals how he lost 100% of his capital on a crooked private mining company management group. Other topics debated are whether retail investors must be bag-holders, how IR reps should not pitch companies and how to gain the human intelligence advantage in junior mining speculation. 0:00 Introduction 0:39 PDAC & Metals Investor Forum 2:36 Retail will always bag-hold? 9:32 Initial due diligence process 14:32 Human intelligence advantage 17:57 Reputation matters 23:24 Brian 20-bagged on Bill's loss 26:57 Brian's 100% loss on crooked management 31:10 People risk & uncertainty 34:01 Proper IR company pitch 35:47 Pre-production skepticism 40:10 100-bagger process 42:27 “Just hang on to hit the bull market” 44:27 Don't take credit for being lucky Brian's website: https://www.juniorstockreview.com/ Bill's Twitter: https://x.com/MiningStockEdu Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Ryan King of Calibre Mining joined MSD from the PDAC show in Toronto this week for an editorial on the reason backing the big merger news between Calibre and Equinox Gold. The conversation highlights he strategic rationale, financial aspects, leadership insights, and future growth potential of the combined entity. The discussion emphasizes the current opportunities in the gold mining sector and the expected benefits for shareholders.

Ian Wagner interviews Peter Akerly of Erdene Resources at the PDAC conference in Toronto. They discuss the company's progress in gold exploration and production in Mongolia, focusing on the Bayan Khundii Gold Project and its expected output. Akerly highlights the strategic partnerships that have been formed to enhance operational efficiency. The conversation also touches on the exploration opportunities in the region and the company's future plans.

Interview with Frederick H. Earnest, President & CEO, Vista Gold CorpOur previous interview: https://www.cruxinvestor.com/posts/vista-gold-tsxvgz-smaller-scale-strategy-to-enhance-economics-5520Recording date: 4th of March, 2025Vista Gold Corp is transforming its approach to developing the Mount Todd gold project in Australia, one of the world's largest undeveloped gold resources with over 9 million ounces. The company is shifting from an ambitious large-scale operation to a more financially viable smaller project that better aligns with current market realities.The original development plan called for a 50,000 tons per day operation with capital expenditure requirements of approximately $1 billion. The revised strategy reduces the scale to 15,000 tons per day with a targeted capital requirement of under $400 million—a 60% reduction in upfront investment costs."For years we talked about Mount Todd as this big project... but a billion dollars US is still a big check to write," explained Fred Earnest, President and CEO of Vista Gold, in a recent interview at the PDAC convention.While the smaller operation would produce 150,000-200,000 ounces of gold annually compared to the original plan's 500,000 ounces, the economics remain compelling. The all-in sustaining costs are estimated at $1,300 per ounce for the smaller operation, compared to $960 per ounce for the larger version, still offering substantial margins at current gold prices.A key advantage of Mount Todd is its advanced permitting status, with all necessary environmental licenses and operating permits already secured. "Literally, I think we could write a letter and we could be in construction in two or three months' time," Earnest noted.The company is well-positioned financially to advance the project, ending 2024 with approximately $17 million in cash—providing a two-year runway without additional funding. This financial stability allows Vista Gold to complete the feasibility study for the smaller-scale approach, which is expected by mid-2025.For eventual project development, Vista Gold is exploring multiple funding avenues, including Australian debt sources like the Northern Australia Infrastructure Fund and equity financing through its North American listings.The strategic pivot comes at a time when the gold mining sector faces challenges in developing new large-scale projects in safe jurisdictions. By focusing on a more manageable development approach, Vista Gold aims to position Mount Todd as an attractive opportunity for mid-tier producers seeking growth through acquisition or partnership.Learn more: https://www.cruxinvestor.com/companies/vista-gold-corporationSign up for Crux Investor: https://cruxinvestor.com

Dave Erfle, Editor of the Junior Miner Junky joins us to discuss yesterday's strong move in gold and silver stocks as opposed to the continued decline in US markets.    Despite the overall market downtrend, gold and silver stocks have shown notable strength. Dave attributes this to several factors, including a drop in the dollar and positive regulatory news from the PDAC conference regarding Mexican silver mining permits. He emphasizes the strong moves made by silver and mining stocks, highlighting that this could signal a more investible sector. Dave also points to Canadian mining's favorable conditions with a higher gold price and a weakening domestic currency.    Looking ahead Dave touches on the importance of watching trading volumes and the potential for a significant breakout in gold prices, which could further drive mining stocks.   Click here to visit the Junior Miner Junky website to learn more about Dave's investment letter.   

Zeus North America, Sierra Madre, Midnight Sun and Red Sea Resources, Kenmare Resources, Myriad Uranium, F3, Atlantic Lithium, Winsome Resources, Apollo Silver, Avino Silver & Gold, Mithril Silver, Guanajuato Silver, Starcore Resources

Fury CEO Tim Clark and QPM CEO Normand Champigny, along with Fury SVP Exploration Bryan Atkinson, explain why Fury acquiring QPM makes sense for the shareholders of both companies. Bill Powers conducted the interview at PDAC 2025. Tim Clark, CEO of Fury, commented: “This Transaction is an exciting opportunity given it doubles Fury's land package in the Eeyou Istchee territory in the James Bay Region of Quebec and unites complementary assets, teams, and investor bases which should ultimately increase shareholder value at both companies. Combining QPM's gold and critical minerals portfolio of exploration projects with Fury's projects and strong balance sheet will not only help improve cost efficiency but also add to the potential for new discoveries.” Normand Champigny, CEO and Director of QPM, commented: “We are very pleased to be entering this combination with Fury. By combining with Fury, QPM's shareholders will benefit from the synergies and cost savings of leveraging the combined company's excellent management team for funding and obtaining required permits to continue drilling at Sakami. We believe that the Transaction with Fury offers for QPM shareholders a high potential for share price appreciation in the current gold market environment. The Transaction demonstrates the progress made with our exploration work to date. Fury has the ability to rapidly advance our assets to identify a large gold mineral resource.” Sponsor: https://furygoldmines.com/ Ticker: FURY Quebec Precious Metals: https://www.qpmcorp.ca/en/ Press Releases discussed: https://furygoldmines.com/fury-gold-mines-limited-to-acquire-quebec-precious-metals-corporation/ 0:00 Intro 0:51 Rationale for Fury's acquisition of QPM 2:53 QPM's Sakami gold project 3:47 QPM's Kipawa REE project 5:17 Fury to “focus on gold in James Bay” 6:31 Normand Champigny will be Fury advisor 7:19 Eleonore South drilling ongoing 7:43 Major interest in Committee Bay project 8:18 BMO & PDAC: “a lot of excitement” Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Sponsor Fury Gold Mines pays MSE a United States dollar seven thousand per month coverage fee. The forward-looking statement found in Fury Gold's most-recent presentation found at www.FuryGoldMines.com applies to everything discussed in this interview. Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Ian Wagner interviews Fabian Baker from Kingsrose Mining at the PDAC conference. They discuss the company's strategic focus on exploration opportunities, particularly the acquisition of the Jakon project in Finland and the ongoing partnership with BHP. Baker elaborates on the unique structure of their alliance with BHP, which allows for significant funding without equity dilution. The conversation also covers the Penikat project, highlighting its potential as a high-grade PGE resource, and concludes with insights into the company's acquisition strategy and future prospects.

Ivan Bebek, Chair and CEO, commented, ““Drilling to date has been completed under budget and on time, and is continuously providing valuable insights into our thesis that a large, mineralized skarn system could be present. Our knowledge of the controls of the system and the vectoring towards key mineralized areas of the skarn continues to improve, while programs have also identified new robust targets for discovery. The identification of the Tipicancha and Antapampa targets are significant as they also offer prospective targets with scale for considerable copper-gold discoveries at Sombrero. With a 100,000-hectare land position, we have barely scratched the surface of this district.” Coppernico has successfully completed approximately 7,100 m of drilling to date having recently commenced hole 18, with ongoing work focusing on key targets within the Ccascabamba target area. Sponsor: https://coppernicometals.com/ Press Release discussed: https://coppernicometals.com/coppernico-provides-update-on-drilling-and-new-epithermal-and-skarn-targets/ TSX:COPR; OTCQB: CPPMF 0:00 Intro 0:39 “We found two more skarn targets” 1:58 “Next three holes are the most exciting” 3:46 Market commentary 5:40 New targets 6:40 Ivan looking to buy copper projects 8:29 Exploration pace 10:07 Treasury management 11:41 “Timing of discovery is so critical” Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Sponsor Coppernico Metals pays MSE a United States dollar seven thousand per month coverage fee. Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

“If you just appreciate what this sector does once momentum gets started. Look at any historic junior chart, once momentum starts it just feeds on itself. What is weird is that it has not really happened; not even gold to three thousand [dollars] has been able to do that. I also think it points to how irrational this sector is. And it is all about momentum,” says private investor Erik Wetterling in this MSE episode. Erik, furthermore, shares his current views on the junior mining sector and how he is managing his portfolio. 0:00 Introduction 0:55 Junior mining value opportunities 5:53 When will gold stocks respond? 14:18 Fort Knox gold audit 18:42 Speculation in non-gold metals 21:54 Separating signal from noise 27:06 PDAC expectations 31:44 Networking necessity 34:21 Stock picks 39:17 Why retail loses money Erik's website: https://www.thehedgelesshorseman.com/ Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. If you buy stock in a company featured on MSE, for your own protection, you should assume that it is MSE's owner personally selling you that stock. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

In this episode, Haydn and Nigel discuss Power Metal's (TSXV: PWM | OTCQB: PWRMF) rare high-grade cesium discoveries, specifically the Case Lake project. They delve into the cost, timelines, and permitting processes compared to other critical minerals like lithium. The conversation includes updates on cesium carbonate market size (2,200 tons per year) and OPEX costs, exploration updates like cesium oxide intercepts greater than 20% in phase three drilling, and test work progress at SGS and Nagrom. The discussion also covers structural mapping exercises, upcoming exploration plans starting in March, and engagement with Canaccord for strategic guidance. They aim to fast-track mining operations and place Power Metals among the top four producers of high-grade cesium, with milestones such as the mineral resource estimate due by the end of Q1 and the PEA by the end of Q2. CHAPTERS

In today's episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director of the USC Center for Molecular Pathway and Drug Discovery, and co-director of the USC Norris Center for Cancer Drug Development in Los Angeles. In our exclusive interview, Dr Lenz discussed the prevalence of RAS mutations in PDAC, the importance of biomarker testing, current treatment strategies for patients with RAS-mutant PDAC, and potential future treatment advances for patients with this disease.

This week's podcast features Jeff Killeen, Director of Policy & Programs at PDAC, in conversation with host Adrian Pocobelli. They dive into the upcoming PDAC conference in Toronto and explore key mining policy issues in Canada. Killeen sheds light on some of the major topics impacting the Canadian mining sector, including the challenges posed by the Alternative Minimum Tax (AMT) and the upcoming expiration of the Mineral Exploration Tax Credit (METC) in March. He also offers insights into potential solutions aimed at streamlining mineral production and processing across the country. All this and more with host Adrian Pocobelli. Music Credits “Rattlesnake Railroad”, “Big Western Sky”, “Western Adventure” and “Battle on the Western Frontier” by Brett Van Donsel (⁠www.incompetech.com⁠). Licensed under Creative Commons: By Attribution 4.0 License ⁠creativecommons.org/licenses/by/4.0⁠ Apple Podcasts:⁠ https://podcasts.apple.com/ca/podcast/the-northern-miner-podcast/id1099281201⁠ Spotify:⁠ https://open.spotify.com/show/78lyjMTRlRwZxQwz2fwQ4K⁠ YouTube:⁠ https://www.youtube.com/@NorthernMiner⁠ Soundcloud:⁠ https://soundcloud.com/northern-miner

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext